APA

Campbell A. M., Morris M., Gallagher R., Boyd R., Carson H., Harkin D. P., Wielogorska E., Elliott C., Savage K. I. & McIntosh S. A. (20191029). Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. : BMJ open.

Chicago

Campbell Aideen M, Morris Melanie, Gallagher Rebecca, Boyd Ruth, Carson Hazel, Harkin D Paul, Wielogorska Ewa, Elliott Christopher, Savage Kienan I and McIntosh Stuart A. 20191029. Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. : BMJ open.

Harvard

Campbell A. M., Morris M., Gallagher R., Boyd R., Carson H., Harkin D. P., Wielogorska E., Elliott C., Savage K. I. and McIntosh S. A. (20191029). Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. : BMJ open.

MLA

Campbell Aideen M, Morris Melanie, Gallagher Rebecca, Boyd Ruth, Carson Hazel, Harkin D Paul, Wielogorska Ewa, Elliott Christopher, Savage Kienan I and McIntosh Stuart A. Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. : BMJ open. 20191029.